Galectin (GALT) Investors Take Profit Following Pop on GR-MD-02 Patent News Monday
Tweet
Share
E-mailGet Alerts GALT Hot Sheet
Join SI Premium – FREE
Galectin Therapeutics (Nasdaq: GALT) shares are pulling back Tuesday, following a strong 63.8 percent move higher Monday on the back of positive carbohydrate-based galectin inhibitor compound news.
Galectin ripped following reports it was issued U.S. Patent and Trademark Office for Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies."
Shares are down over 8 percent in early trading.
Galectin ripped following reports it was issued U.S. Patent and Trademark Office for Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies."
Shares are down over 8 percent in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- Affirm stock drops on report Walmart-backed fintech One is launching BNPL; Mizuho says 'concerns overblown'
- Tencent (TCEHY) shares jump on 'Dungeon and Fighter' launch update
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
